<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALDARA- imiquimod cream </strong><br>Medicis Pharmaceutical Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Aldara safely and effectively. See full prescribing information for Aldara. <br><br> Aldara<span class="Sup">®</span> (imiquimod) Cream, 5% <br> For topical use only <br> Initial U.S. Approval: 1997</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Aldara Cream is indicated for the topical treatment of: </p>
<dl>
<dt>•</dt>
<dd>Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults (<a href="#S1.1">1.1</a>)</dd>
<dt>•</dt>
<dd>Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured (<a href="#S1.2">1.2</a>)</dd>
<dt>•</dt>
<dd>External genital and perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>/condyloma acuminata in patients 12 years old or older (<a href="#S1.3">1.3</a>)</dd>
</dl>
<p class="Highlighta">Limitations of Use: Efficacy was not demonstrated for <span class="product-label-link" type="condition" conceptid="141216" conceptname="Molluscum contagiosum infection">molluscum contagiosum</span> in children aged 2–12 (<a href="#S1.4">1.4</a>, <a href="#S8.4">8.4</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Aldara Cream is not for oral, ophthalmic, or intravaginal use. (<a href="#S2">2</a>) </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic keratosis</span>: 2 times per week for a full 16 weeks (<a href="#S2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>Superficial basal cell carcinoma: 5 times per week for a full 6 weeks (<a href="#S2.2">2.2</a>)</dd>
<dt>•</dt>
<dd>External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span> (EGW): 3 times per week until total clearance or a maximum of 16 weeks (<a href="#S2.3">2.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Aldara (imiquimod) Cream, 5%, is supplied in single-use packets (12 per box), each of which contains 250 mg of the cream, equivalent to 12.5 mg of imiquimod. (<a href="#S3">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>None (<a href="#S4">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Intense local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> can occur (e.g., skin <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">weeping</span>, erosion). Dosing interruption may be required (<a href="#S2">2</a>, <a href="#S5.1">5.1</a>, <a href="#S6">6</a>)</dd>
<dt>•</dt>
<dd>Severe local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> of the female external genitalia can lead to severe vulvar <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. Severe vulvar <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> can lead to <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; dosing should be interrupted or discontinued.</dd>
<dt>•</dt>
<dd>Flu-like systemic signs and symptoms including <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> may occur. Dosing interruption may be required (<a href="#S2">2</a>, <a href="#S5.2">5.2</a>, <a href="#S6">6</a>)</dd>
<dt>•</dt>
<dd>Avoid exposure to sunlight and sunlamps. Wear sunscreen daily (<a href="#S5.3">5.3</a>).</dd>
<dt>•</dt>
<dd>Safety and efficacy have not been established for repeat courses of treatment to the same area for AK. (<a href="#S5.4">5.4</a>)</dd>
<dt>•</dt>
<dd>Aldara Cream is not recommended for treatment of BCC subtypes other than the superficial variant, i.e., sBCC. (<a href="#S5.5">5.5</a>)</dd>
<dt>•</dt>
<dd>Treatment of urethral, intra-vaginal, cervical, rectal or intra-anal viral disease is not recommended. (<a href="#S5.6">5.6</a>)</dd>
<dt>•</dt>
<dd>Safety and efficacy in immunosuppressed patients have not been established (<a href="#S1.5">1.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt;28%) are <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> or local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>: <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, flaking/scaling/dryness, <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriation</span>, erosion, ulceration. Other reported reactions (≥ 1%) include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#S6.1">6.1</a>, <a href="#S6.2">6.2</a>, <a href="#S6.3">6.3</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Medicis, The Dermatology Company at 1-800-328-0255 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Superficial Basal Cell Carcinoma</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Limitations of Use</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 Unevaluated Populations</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Superficial Basal Cell Carcinoma</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammatory Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Systemic Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Ultraviolet Light Exposure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Unevaluated Uses: <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Unevaluated Uses: Superficial Basal Cell Carcinoma</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Unevaluated Uses: External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience: <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience: Superficial Basal Cell Carcinoma</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Clinical Trials Experience: External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Clinical Trials Experience: Dermal Safety Studies</a></h2>
<h2><a href="#section-6.5" class="toc">6.5 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></a></h2>
<h2><a href="#section-12.2" class="toc">14.2 Superficial Basal Cell Carcinoma</a></h2>
<h2><a href="#section-12.3" class="toc">14.3 External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 General Information: All Indications</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>: All Indications</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Systemic Reactions: All Indications</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Patients Being Treated for <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span> (AK)</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Patients Being Treated for Superficial Basal Cell Carcinoma (sBCC)</a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Patients Being Treated for External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></h2>
<p class="First">Aldara Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Superficial Basal Cell Carcinoma</h2>
<p class="First">Aldara Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.</p>
<p>The histological diagnosis of <span class="Underline">superficial</span> basal cell carcinoma should be established prior to treatment, since safety and efficacy of Aldara Cream have not been established for other types of basal cell carcinomas, including nodular and morpheaform (fibrosing or sclerosing) types.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></h2>
<p class="First">Aldara Cream is indicated for the treatment of external genital and perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>/condyloma acuminata in patients 12 years old or older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Limitations of Use</h2>
<p class="First">Aldara Cream has been evaluated in children ages 2 to 12 years with <span class="product-label-link" type="condition" conceptid="141216" conceptname="Molluscum contagiosum infection">molluscum contagiosum</span> and these studies failed to demonstrate efficacy <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5 Unevaluated Populations</h2>
<p class="First">The safety and efficacy of Aldara Cream in immunosuppressed patients have not been established.</p>
<p>Aldara Cream should be used with caution in patients with pre-existing autoimmune conditions.</p>
<p>The efficacy and safety of Aldara Cream have not been established for patients with Basal Cell <span class="product-label-link" type="condition" conceptid="4010103" conceptname="Intradermal nevus">Nevus</span> Syndrome or <span class="product-label-link" type="condition" conceptid="4198562" conceptname="Xeroderma">Xeroderma</span> Pigmentosum.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">The application frequency for Aldara Cream is different for each indication.</span></p>
<p>Aldara is not for oral, ophthalmic, or intravaginal use.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></h2>
<p class="First">Aldara Cream should be applied 2 times per week for a full 16 weeks to a defined treatment area on the face or scalp (but not both concurrently). The treatment area is defined as one contiguous area of approximately 25 cm<span class="Sup">2</span> (e.g., 5 cm × 5 cm) on the face (e.g., forehead or one cheek) <span class="Bold">or</span> on the scalp. Examples of 2 times per week application schedules are Monday and Thursday, or Tuesday and Friday. Aldara Cream should be applied to the entire treatment area and rubbed in until the cream is no longer visible. No more than one packet of Aldara Cream should be applied to the contiguous treatment area at each application. <span class="Bold">Aldara Cream should be applied prior to normal sleeping hours and left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water</span>. The prescriber should demonstrate the proper application technique to maximize the benefit of Aldara Cream therapy.</p>
<p>It is recommended that patients wash their hands before and after applying Aldara Cream. Before applying the cream, the patient should wash the treatment area with mild soap and water and allow the area to dry thoroughly (at least 10 minutes).</p>
<p>Contact with the eyes, lips and nostrils should be avoided.</p>
<p>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> in the treatment area are common <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1</a>, <a href="#S6.5">6.5)</a>].</span> A rest period of several days may be taken if required by the patient's <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or severity of the local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>. <span class="Bold">However, the treatment period should not be extended beyond 16 weeks due to missed doses or rest periods</span>. Response to treatment cannot be adequately assessed until resolution of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Lesions that do not respond to treatment should be carefully re-evaluated and management reconsidered.</p>
<p>Aldara Cream is packaged in single-use packets, with 12 packets supplied per box. <span class="Bold">Patients should be prescribed no more than 36 packets for the 16-week treatment period</span>. Unused packets should be discarded. Partially-used packets should be discarded and not reused.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Superficial Basal Cell Carcinoma</h2>
<p class="First"><span class="Bold">Aldara Cream should be applied 5 times per week for a full 6 weeks to a biopsy-confirmed superficial basal cell carcinoma</span>. An example of a 5 times per week application schedule is to apply Aldara Cream, once per day, Monday through Friday. <span class="Bold">Aldara Cream should be applied prior to normal sleeping hours and left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water</span>. The prescriber should demonstrate the proper application technique to maximize the benefit of Aldara Cream therapy.</p>
<p>It is recommended that patients wash their hands before and after applying Aldara Cream. The patient should wash the treatment area with mild soap and water before applying the cream, and allow the area to dry thoroughly.</p>
<p>The target tumor should have a maximum diameter of 2 cm and be located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet). The treatment area should include a 1 cm margin of skin around the tumor. Sufficient cream should be applied to cover the treatment area, including 1 centimeter of skin surrounding the tumor. Aldara Cream should be rubbed into the treatment area until the cream is no longer visible.</p>
<a name="_RefID0ESIAC"></a><table width="100%">
<caption><span>Table 1. Amount of Aldara Cream to Use for sBCC</span></caption>
<col width="30%">
<col width="35%">
<col width="35%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Target Tumor Diameter</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Size of Cream Droplet to be Used (diameter)</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Approximate Amount of</span><br><span class="Bold">Aldara to be Used</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.5 to &lt; 1.0 cm</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">4 mm</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">10 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 1.0 to &lt; 1.5 cm</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 mm</p></td>
<td class="Botrule Rrule" align="center"><p class="First">25 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 1.5 to 2.0 cm</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7 mm</p></td>
<td class="Botrule Rrule" align="center"><p class="First">40 mg</p></td>
</tr>
</tbody>
</table>
<p>Contact with the eyes, lips and nostrils should be avoided.</p>
<p>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> in the treatment area are common <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2</a>, <a href="#S6.5">6.5)</a>].</span> A rest period of several days may be taken if required by the patient's <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or severity of the local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>.</p>
<p><span class="Bold">Early clinical clearance cannot be adequately assessed until resolution of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (e.g., 12 weeks post-treatment)</span>. Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or other findings (e.g., <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) may require that a patient be seen sooner than the post-treatment assessment for clinical clearance. If there is clinical evidence of persistent tumor at the post-treatment assessment for clinical clearance, a biopsy or other alternative intervention should be considered. Lesions that do not respond to therapy should be carefully re-evaluated and management reconsidered; the safety and efficacy of a repeat course of Aldara Cream treatment have not been established. If any suspicious lesion arises in the treatment area at any time after a determination of clinical clearance, the patient should seek a medical evaluation <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>Aldara Cream is packaged in single-use packets, with 12 packets supplied per box. <span class="Bold">Patients should be prescribed no more than 36 packets for the 6-week treatment period</span>. Unused packets should be discarded. Partially-used packets should be discarded and not reused.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></h2>
<p class="First">Aldara Cream should be applied 3 times per week to external genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>. Aldara Cream treatment should continue until there is total clearance of the genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> or for a maximum of 16 weeks. Examples of 3 times per week application schedules are: Monday, Wednesday, Friday or Tuesday, Thursday, Saturday. <span class="Bold">Aldara Cream should be applied prior to normal sleeping hours and left on the skin for 6 –10 hours, after which time the cream should be removed by washing the area with mild soap and water</span>. The prescriber should demonstrate the proper application technique to maximize the benefit of Aldara Cream therapy.</p>
<p>It is recommended that patients wash their hands before and after applying Aldara Cream.</p>
<p>A <span class="Underline">thin</span> layer of Aldara Cream should be applied to the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> area and rubbed in until the cream is no longer visible. The application site should not be occluded. Following the treatment period the cream should be removed by washing the treated area with mild soap and water.</p>
<p>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> at the treatment site are common <span class="Italics">[see <a href="#S6.3">Adverse Reactions (6.3</a>, <a href="#S6.5">6.5)</a>]</span>. A rest period of several days may be taken if required by the patient's <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or severity of the local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>. Treatment may resume once the reaction subsides. Non-occlusive dressings such as cotton gauze or cotton underwear may be used in the management of <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</p>
<p>Aldara Cream is packaged in single-use packets which contain sufficient cream to cover a <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> area of up to 20 cm<span class="Sup">2</span>; use of excessive amounts of cream should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Aldara (imiquimod) Cream, 5%, is supplied in single-use packets each of which contains 250 mg of the cream, equivalent to 12.5 mg of imiquimod. Aldara Cream is supplied in boxes of 12 packets each.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammatory Reactions</span></h2>
<p class="First">Intense local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> including skin <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">weeping</span> or erosion can occur after few applications of Aldara Cream and may require an interruption of dosing <span class="Italics">[see <a href="#S2">Dosage and Administration (2)</a></span>and<span class="Italics"><a href="#S6">Adverse Reactions (6)</a>]</span>. Aldara Cream has the potential to exacerbate inflammatory conditions of the skin, including <span class="product-label-link" type="condition" conceptid="434314" conceptname="Chronic graft-versus-host disease">chronic graft versus host disease</span>.</p>
<p>Severe local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> of the female external genitalia can lead to severe vulvar <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</p>
<p>Severe vulvar <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> can lead to <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Dosing should be interrupted or discontinued for severe vulvar <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</p>
<p>Administration of Aldara Cream is not recommended until the skin is completely healed from any previous drug or surgical treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Systemic Reactions</h2>
<p class="First">Flu-like signs and symptoms may accompany, or even precede, local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span> and may include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>. An interruption of dosing should be considered <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Ultraviolet Light Exposure</h2>
<p class="First">Exposure to sunlight (including sunlamps) should be avoided or minimized during use of Aldara Cream because of concern for heightened sunburn susceptibility. Patients should be warned to use protective clothing (e.g., a hat) when using Aldara Cream. Patients with sunburn should be advised not to use Aldara Cream until fully recovered. Patients who may have considerable sun exposure, e.g., due to their occupation, and those patients with inherent sensitivity to sunlight should exercise caution when using Aldara Cream.</p>
<p>Aldara Cream shortened the time to <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumor</span> formation in an animal photoco-carcinogenicity study <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>. The enhancement of ultraviolet carcinogenicity is not necessarily dependent on phototoxic mechanisms. Therefore, patients should minimize or avoid natural or artificial sunlight exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Unevaluated Uses: <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></h2>
<p class="First">Safety and efficacy have not been established for Aldara Cream in the treatment of <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> with repeated use, i.e. more than one treatment course, in the same area.</p>
<p>The safety of Aldara Cream applied to areas of skin greater than 25 cm<span class="Sup">2</span> (e.g., 5 cm × 5 cm) for the treatment of <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> has not been established <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Unevaluated Uses: Superficial Basal Cell Carcinoma</h2>
<p class="First">The safety and efficacy of Aldara Cream have not been established for other types of basal cell carcinomas (BCC), including nodular and morpheaform (fibrosing or sclerosing) types. <span class="Bold">Aldara Cream is not recommended for treatment of BCC subtypes other than the superficial variant (i.e., sBCC)</span>. Patients with sBCC treated with Aldara Cream should have regular follow-up of the treatment site <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>The safety and efficacy of treating sBCC lesions on the face, head and anogenital area have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Unevaluated Uses: External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></h2>
<p class="First">Aldara Cream has not been evaluated for the treatment of urethral, intra-vaginal, cervical, rectal, or intra-anal human <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> viral disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience: <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></h2>
<p class="First">The data described below reflect exposure to Aldara Cream or vehicle in 436 subjects enrolled in two double-blind, vehicle-controlled studies. Subjects applied Aldara Cream or vehicle to a 25 cm<span class="Sup">2</span> contiguous treatment area on the face or scalp 2 times per week for 16 weeks.</p>
<a name="_RefID0ELGAE"></a><table width="80%">
<caption><span>Table 2: Selected Adverse Reactions Occurring in &gt; 1% of Aldara-Treated Subjects and at a Greater Frequency than with Vehicle in the Combined Studies (<span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span>)</span></caption>
<col width="37%">
<col width="28%">
<col width="28%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Preferred Term</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Aldara Cream (n=215)</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Vehicle (n=221)</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span></p></td>
<td class="Toprule"><p class="First">71 (33%)</p></td>
<td class="Toprule"><p class="First">32 (14%)</p></td>
</tr>
<tr>
<td><p class="First">Upper Resp Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td><p class="First">33 (15%)</p></td>
<td><p class="First">27 (12%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td><p class="First">16 (7%)</p></td>
<td><p class="First">14 (6%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td><p class="First">11 (5%)</p></td>
<td><p class="First">7 (3%)</p></td>
</tr>
<tr>
<td><p class="First">Carcinoma Squamous</p></td>
<td><p class="First">8 (4%)</p></td>
<td><p class="First">5 (2%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">6 (3%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span></p></td>
<td><p class="First">4 (2%)</p></td>
<td><p class="First">3 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Fibrillation Atrial</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection Viral</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Botrule"><p class="First">3 (1%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<a name="_RefID0ELJAE"></a><table width="80%">
<caption><span>Table 3: <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reactions</span> Reported by &gt; 1% of Aldara-Treated Subjects and at a Greater Frequency than with Vehicle in the Combined Studies (<span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span>)</span></caption>
<col width="37%">
<col width="28%">
<col width="28%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Included Term</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Aldara Cream (n=215)</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Vehicle (n=221)</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></p></td>
<td class="Toprule"><p class="First">44 (20%)</p></td>
<td class="Toprule"><p class="First">17 (8%)</p></td>
</tr>
<tr>
<td><p class="First">Burning</p></td>
<td><p class="First">13 (6%)</p></td>
<td><p class="First">4 (2%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></p></td>
<td><p class="First">7 (3%)</p></td>
<td><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span></p></td>
<td><p class="First">6 (3%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td><p class="First">6 (3%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></p></td>
<td><p class="First">5 (2%)</p></td>
<td><p class="First">3 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span></p></td>
<td><p class="First">4 (2%)</p></td>
<td><p class="First">3 (1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Irritation</p></td>
<td class="Botrule"><p class="First">4 (2%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<p>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> were collected independently of the adverse reaction "<span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reaction</span>" in an effort to provide a better picture of the specific types of local reactions that might be seen. The most frequently reported local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> were <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, flaking/scaling/dryness, and <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting. The prevalence and severity of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that occurred during controlled studies are shown in the following table.</p>
<a name="_RefID0EILAE"></a><table width="100%">
<caption><span>Table 4: Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> in the Treatment Area as Assessed by the Investigator (<span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span>)</span></caption>
<col width="28%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="18%">
<thead>
<tr class="First">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Aldara Cream (n=215)</span></th>
<th class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Vehicle (n=220)</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">All Grades</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Botrule" align="left" valign="top"><span class="Bold">Severe</span></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">All Grades</span><a href="#footnote-1" class="Sup">*</a>
</th>
<th class="Botrule" align="left" valign="top"><span class="Bold">Severe</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mild, Moderate, or Severe</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p></td>
<td class="Toprule"><p class="First">209 (97%)</p></td>
<td class="Toprule"><p class="First">38 (18%)</p></td>
<td class="Toprule"><p class="First">206 (93%)</p></td>
<td class="Toprule"><p class="First">5 (2%)</p></td>
</tr>
<tr>
<td><p class="First">Flaking/Scaling/Dryness</p></td>
<td><p class="First">199 (93%)</p></td>
<td><p class="First">16 (7%)</p></td>
<td><p class="First">199 (91%)</p></td>
<td><p class="First">7 (3%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">Scabbing</span>/Crusting</p></td>
<td><p class="First">169 (79%)</p></td>
<td><p class="First">18 (8%)</p></td>
<td><p class="First">92 (42%)</p></td>
<td><p class="First">4 (2%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td><p class="First">106 (49%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">22 (10%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First">Erosion/Ulceration</p></td>
<td><p class="First">103 (48%)</p></td>
<td><p class="First">5 (2%)</p></td>
<td><p class="First">20 (9%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">Weeping</span>/Exudate</p></td>
<td><p class="First">45 (22%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">3 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Vesicles</span></p></td>
<td class="Botrule"><p class="First">19 (9%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">2 (1%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<p>The adverse reactions that most frequently resulted in clinical intervention (e.g., rest periods, withdrawal from study) were local skin and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>. Overall, in the clinical studies, 2% (5/215) of subjects discontinued for local skin/<span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>. Of the 215 subjects treated, 35 subjects (16%) on Aldara Cream and 3 of 220 subjects (1%) on vehicle cream had at least one rest period. Of these Aldara Cream subjects, 32 (91%) resumed therapy after a rest period.</p>
<p>In the AK studies, 22 of 678 (3.2%) of Aldara-treated subjects developed treatment site <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that required a rest period off Aldara Cream and were treated with antibiotics (19 with oral and 3 with topical).</p>
<p>Of the 206 Aldara subjects with both baseline and 8-week post-treatment <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> assessments, 6 (2.9%) had a greater degree of <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> scores at 8-weeks post-treatment than at baseline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience: Superficial Basal Cell Carcinoma</h2>
<p class="First">The data described below reflect exposure to Aldara Cream or vehicle in 364 subjects enrolled in two double-blind, vehicle-controlled studies. Subjects applied Aldara Cream or vehicle 5 times per week for 6 weeks. The incidence of adverse reactions reported by &gt; 1% of subjects during the studies is summarized below.</p>
<a name="_RefID0EYOAE"></a><table width="80%">
<caption><span>Table 5: Selected Adverse Reactions Reported by &gt; 1% of Aldara-Treated Subjects and at a Greater Frequency than with Vehicle in the Combined Studies (Superficial Basal Cell Carcinoma)</span></caption>
<col width="38%">
<col width="27%">
<col width="27%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Preferred Term</span></th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Aldara Cream (n=185)</span><br><span class="Bold">N%</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Vehicle (n=179)</span><br><span class="Bold"> N%</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span></p></td>
<td class="Toprule" align="center"><p class="First">52 (28%)</p></td>
<td class="Toprule" align="center"><p class="First">5 (3%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center"><p class="First">14 (8%)</p></td>
<td align="center"><p class="First">4 (2%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> </p></td>
<td align="center"><p class="First">7 (4%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First">Upper Resp Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td align="center"><p class="First">6 (3%)</p></td>
<td align="center"><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td align="center"><p class="First">5 (3%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></p></td>
<td align="center"><p class="First">5 (3%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">4 (2%)</p></td>
<td align="center"><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </p></td>
<td align="center"><p class="First">4 (2%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="center"><p class="First">3 (2%)</p></td>
<td align="center"><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></p></td>
<td align="center"><p class="First">3 (2%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td align="center"><p class="First">3 (2%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td align="center"><p class="First">2 (1%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td align="center"><p class="First">2 (1%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>  </p></td>
<td align="center"><p class="First">2 (1%)</p></td>
<td align="center"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td align="center"><p class="First">2 (1%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>  </p></td>
<td class="Botrule" align="center"><p class="First">2 (1%)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<p>The most frequently reported adverse reactions were local skin and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, erosion, flaking/scaling, <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and burning at the application site. The incidence of <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> reported by &gt; 1% of the subjects during the 6 week treatment period is summarized in Table 6.</p>
<a name="_RefID0EZRAE"></a><table width="80%">
<caption><span>Table 6: <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reactions</span> Reported by &gt; 1% of Aldara-Treated Subjects and at a Greater Frequency than with Vehicle in the Combined Studies (Superficial Basal Cell Carcinoma)</span></caption>
<col width="37%">
<col width="28%">
<col width="28%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Included Term</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Aldara Cream (n=185)</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Vehicle (n=179)</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></p></td>
<td class="Toprule"><p class="First">30 (16%)</p></td>
<td class="Toprule"><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td><p class="First">Burning</p></td>
<td><p class="First">11 (6%)</p></td>
<td><p class="First">2 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td><p class="First">6 (3%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></p></td>
<td><p class="First">4 (2%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p></td>
<td><p class="First">3 (2%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">Papule</span>(s)</p></td>
<td><p class="First">3 (2%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span></p></td>
<td><p class="First">2 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule"><p class="First">2 (1%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<p>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> were collected independently of the adverse reaction "<span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reaction</span>" in an effort to provide a better picture of the specific types of local reactions that might be seen. The prevalence and severity of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that occurred during controlled studies are shown in the following table.</p>
<a name="_RefID0EWTAE"></a><table width="100%">
<caption><span>Table 7: Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> in the Treatment Area as Assessed by the Investigator (Superficial Basal Cell Carcinoma)</span></caption>
<col width="28%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="18%">
<thead>
<tr class="First">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Aldara Cream (n=184)</span></th>
<th class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Vehicle (n=178)</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">All Grades</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</th>
<th class="Botrule" align="center" valign="top"><span class="Bold">Severe</span></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">All Grades</span><a href="#footnote-2" class="Sup">*</a>
</th>
<th class="Botrule" align="center" valign="top"><span class="Bold">Severe</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Mild, Moderate, or Severe</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>    </p></td>
<td class="Toprule" align="center"><p class="First">184 (100%)</p></td>
<td class="Toprule" align="center"><p class="First">57 (31%)</p></td>
<td class="Toprule" align="center"><p class="First">173 (97%)</p></td>
<td class="Toprule" align="center"><p class="First">4 (2%)</p></td>
</tr>
<tr>
<td><p class="First">Flaking/Scaling  </p></td>
<td align="center"><p class="First">167 (91%)</p></td>
<td align="center"><p class="First">7 (4%)</p></td>
<td align="center"><p class="First">135 (76%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span>   </p></td>
<td align="center"><p class="First">154 (84%)</p></td>
<td align="center"><p class="First">11 (6%)</p></td>
<td align="center"><p class="First">94 (53%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">Scabbing</span>/Crusting  </p></td>
<td align="center"><p class="First">152 (83%)</p></td>
<td align="center"><p class="First">35 (19%)</p></td>
<td align="center"><p class="First">61 (34%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td align="center"><p class="First">143 (78%)</p></td>
<td align="center"><p class="First">13 (7%)</p></td>
<td align="center"><p class="First">64 (36%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First">Erosion</p></td>
<td align="center"><p class="First">122 (66%)</p></td>
<td align="center"><p class="First">23 (13%)</p></td>
<td align="center"><p class="First">25 (14%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First">Ulceration</p></td>
<td align="center"><p class="First">73 (40%)</p></td>
<td align="center"><p class="First">11 (6%)</p></td>
<td align="center"><p class="First">6 (3%)</p></td>
<td align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Vesicles</span></p></td>
<td class="Botrule" align="center"><p class="First">57 (31%)</p></td>
<td class="Botrule" align="center"><p class="First">3 (2%)</p></td>
<td class="Botrule" align="center"><p class="First">4 (2%)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<p>The adverse reactions that most frequently resulted in clinical intervention (e.g., rest periods, withdrawal from study) were local skin and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>; 10% (19/185) of subjects received rest periods. The average number of doses not received per subject due to rest periods was 7 doses with a range of 2 to 22 doses; 79% of subjects (15/19) resumed therapy after a rest period. Overall, in the clinical studies, 2% (4/185) of subjects discontinued for local skin/<span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>.</p>
<p>In the sBCC studies, 17 of 1266 (1.3%) Aldara-treated subjects developed treatment site <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that required a rest period and treatment with antibiotics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Clinical Trials Experience: External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></h2>
<p class="First">In controlled clinical trials for <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, the most frequently reported adverse reactions were local skin and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>.</p>
<p>Some subjects also reported systemic reactions. Overall, 1.2% (4/327) of the subjects discontinued due to local skin/<span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>. The incidence and severity of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> during controlled clinical trials are shown in Table 8.</p>
<a name="_RefID0EMXAE"></a><table width="100%">
<caption><span>Table 8: Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> in the Treatment Area as Assessed by the Investigator (External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span>)</span></caption>
<col width="13%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<thead>
<tr class="First">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Aldara Cream</span></th>
<th class="Botrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Vehicle</span></th>
</tr>
<tr>
<th align="left" valign="top"></th>
<th align="center" colspan="2" valign="top"><span class="Bold">Females (n=114)</span></th>
<th align="center" colspan="2" valign="top"><span class="Bold">Males (n=156)</span></th>
<th align="center" colspan="2" valign="top"><span class="Bold">Females (n=99)</span></th>
<th align="center" colspan="2" valign="top"><span class="Bold">Males (n=157)</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">All Grades</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th class="Botrule" align="left" valign="bottom"><span class="Bold">Severe</span></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">All Grades</span><a href="#footnote-3" class="Sup">*</a>
</th>
<th class="Botrule" align="left" valign="bottom"><span class="Bold">Severe</span></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">All Grades</span><a href="#footnote-3" class="Sup">*</a>
</th>
<th class="Botrule" align="left" valign="bottom"><span class="Bold">Severe</span></th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">All Grades</span><a href="#footnote-3" class="Sup">*</a>
</th>
<th class="Botrule" align="left" valign="bottom"><span class="Bold">Severe</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Mild, Moderate, or Severe</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p></td>
<td class="Toprule"><p class="First">74 (65%)</p></td>
<td class="Toprule"><p class="First">4 (4%)</p></td>
<td class="Toprule"><p class="First">90 (58%)</p></td>
<td class="Toprule"><p class="First">6 (4%)</p></td>
<td class="Toprule"><p class="First">21 (21%)</p></td>
<td class="Toprule"><p class="First">0 (0%)</p></td>
<td class="Toprule"><p class="First">34 (22%)</p></td>
<td class="Toprule"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First">Erosion</p></td>
<td><p class="First">35 (31%)</p></td>
<td><p class="First">1 (1%)</p></td>
<td><p class="First">47 (30%)</p></td>
<td><p class="First">2 (1%)</p></td>
<td><p class="First">8 (8%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">10 (6%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">Excoriation</span>/<br>Flaking</p></td>
<td><p class="First">21 (18%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">40 (26%)</p></td>
<td><p class="First">1 (1%)</p></td>
<td><p class="First">8 (8%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">12 (8%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td><p class="First">20 (18%)</p></td>
<td><p class="First">1 (1%)</p></td>
<td><p class="First">19 (12%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">5 (5%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">1 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">Scabbing</span></p></td>
<td><p class="First">4 (4%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">20 (13%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">4 (3%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></p></td>
<td><p class="First">6 (5%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">11 (7%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">2 (2%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">3 (2%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td><p class="First">Ulceration</p></td>
<td><p class="First">9 (8%)</p></td>
<td><p class="First">3 (3%)</p></td>
<td><p class="First">7 (4%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">1 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">1 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Vesicles</span></p></td>
<td class="Botrule"><p class="First">3 (3%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">3 (2%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
<p>Remote site <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> were also reported. The severe remote site <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> reported for females were <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (3%), ulceration (2%), and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (1%); and for males, erosion (2%), and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, and <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriation</span>/flaking (each 1%).</p>
<p>Selected adverse reactions judged to be probably or possibly related to Aldara Cream are listed below.</p>
<a name="_RefID0EH4AE"></a><table width="100%">
<caption><span>Table 9: Selected Treatment Related Reactions (External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span>)</span></caption>
<col width="30%">
<col width="18%">
<col width="17%">
<col width="18%">
<col width="17%">
<thead>
<tr class="First">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Females</span></th>
<th class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Males</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="top"></th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">Aldara Cream</span><br><span class="Bold">(n=117)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">Vehicle</span><br><span class="Bold">(n=103)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">Aldara Cream</span><br><span class="Bold">(n=156)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">Vehicle</span><br><span class="Bold">(n=158)</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Incidences reported without regard to causality with Aldara Cream.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="Bold">Application Site Disorders:</span></p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reactions</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">Wart</span> Site:</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></p></td>
<td><p class="First">38 (32%)</p></td>
<td><p class="First">21 (20%)</p></td>
<td><p class="First">34 (22%)</p></td>
<td><p class="First">16 (10%)</p></td>
</tr>
<tr>
<td><p class="First">Burning   </p></td>
<td><p class="First">30 (26%)</p></td>
<td><p class="First">12 (12%)</p></td>
<td><p class="First">14 (9%)</p></td>
<td><p class="First">8 (5%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>    </p></td>
<td><p class="First">9 (8%)</p></td>
<td><p class="First">2 (2%)</p></td>
<td><p class="First">3 (2%)</p></td>
<td><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td><p class="First">Soreness    </p></td>
<td><p class="First">3 (3%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infection</span></span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td><p class="First">13 (11%)</p></td>
<td><p class="First">3 (3%)</p></td>
<td><p class="First">3 (2%)</p></td>
<td><p class="First">1 (1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Systemic Reactions:</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">5 (4%)</p></td>
<td><p class="First">3 (3%)</p></td>
<td><p class="First">8 (5%)</p></td>
<td><p class="First">3 (2%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</p></td>
<td><p class="First">4 (3%)</p></td>
<td><p class="First">2 (2%)</p></td>
<td><p class="First">2 (1%)</p></td>
<td><p class="First">0 (0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule"><p class="First">1 (1%)</p></td>
<td class="Botrule"><p class="First">0 (0%)</p></td>
<td class="Botrule"><p class="First">2 (1%)</p></td>
<td class="Botrule"><p class="First">1 (1%)</p></td>
</tr>
</tbody>
</table>
<p>Adverse reactions judged to be possibly or probably related to Aldara Cream and reported by more than 1% of subjects included:</p>
<p><span class="Bold">Application Site Disorders:</span> burning, hypopigmentation, irritation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sensitivity, soreness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span></p>
<p><span class="Bold">Remote Site Reactions:</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span></p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms</p>
<p><span class="Bold">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Bold">Gastro-Intestinal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p><span class="Bold">Musculo-Skeletal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Clinical Trials Experience: Dermal Safety Studies</h2>
<p class="First">Provocative repeat insult patch test studies involving induction and challenge phases produced no evidence that Aldara Cream causes photoallergenicity or contact sensitization in healthy skin; however, cumulative irritancy testing revealed the potential for Aldara Cream to cause irritation, and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> were reported in the clinical studies <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.5"></a><a name="section-6.5"></a><p></p>
<h2>6.5 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Aldara Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold">Application Site Disorders:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> at the application site</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">capillary leak syndrome</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p><span class="Bold">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span></p>
<p><span class="Bold">Gastro-Intestinal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Bold">Hematological:</span> decreases in red cell, white cell and platelet counts (including <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>), <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span></p>
<p><span class="Bold">Hepatic:</span> abnormal liver function</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> herpes simplex</p>
<p><span class="Bold">Musculo-Skeletal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="Bold">Neuropsychiatric:</span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (including <span class="product-label-link" type="condition" conceptid="444413" conceptname="Febrile convulsion">febrile convulsions</span>), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> aggravation, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Bold">Urinary System Disorders:</span> <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4058388" conceptname="Hypertrophic scar">hypertrophic scar</span></p>
<p><span class="Bold">Vascular:</span> Henoch-Schönlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> syndrome</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_6d766a93-d949-4fe9-a404-54ec6e4831dc"></a><a name="section-7.1.1"></a><p></p>
<p class="First">Pregnancy Category C:</p>
<p>Note: The Maximum Recommended Human Dose (MRHD) was set at 2 packets per treatment of Aldara Cream (25 mg imiquimod) for the animal multiple of human exposure ratios presented in this label. If higher doses than 2 packets of Aldara Cream are used clinically, then the animal multiple of human exposure would be reduced for that dose. A non-proportional increase in systemic exposure with increased dose of Aldara Cream was noted in the clinical pharmacokinetic study conducted in <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> subjects <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The AUC after topical application of 6 packets of Aldara Cream was 8 fold greater than the AUC after topical application of 2 packets of Aldara Cream in <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> subjects. Therefore, if a dose of 6 packets per treatment of Aldara Cream was topically administered to an individual, then the animal multiple of human exposure would be either 1/3 of the value provided in the label (based on body surface area comparisons) or 1/8 of the value provided in the label (based on AUC comparisons). The animal multiples of human exposure calculations were based on weekly dose comparisons for the carcinogenicity studies described in this label. The animal multiples of human exposure calculations were based on daily dose comparisons for the reproductive toxicology studies described in this label.</p>
<p>Systemic embryofetal development studies were conducted in rats and rabbits. Oral doses of 1, 5 and 20 mg/kg/day imiquimod were administered during the period of organogenesis (gestational days 6–15) to pregnant female rats. In the presence of maternal toxicity, fetal effects noted at 20 mg/kg/day (577× MRHD based on AUC comparisons) included increased resorptions, decreased fetal body weights, delays in skeletal ossification, bent limb bones, and two fetuses in one litter (2 of 1567 fetuses) demonstrated <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>, protruding tongues and low-set ears. No treatment related effects on embryofetal toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at 5 mg/kg/day (98× MRHD based on AUC comparisons).</p>
<p>Intravenous doses of 0.5, 1 and 2 mg/kg/day imiquimod were administered during the period of organogenesis (gestational days 6–18) to pregnant female rabbits. No treatment related effects on embryofetal toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at 2 mg/kg/day (1.5× MRHD based on BSA comparisons), the highest dose evaluated in this study, or 1 mg/kg/day (407× MRHD based on AUC comparisons).</p>
<p>A combined fertility and peri- and post-natal development study was conducted in rats. Oral doses of 1, 1.5, 3 and 6 mg/kg/day imiquimod were administered to male rats from 70 days prior to mating through the mating period and to female rats from 14 days prior to mating through parturition and lactation. No effects on growth, fertility, reproduction or post-natal development were noted at doses up to 6 mg/kg/day (87× MRHD based on AUC comparisons), the highest dose evaluated in this study. In the absence of maternal toxicity, bent limb bones were noted in the F1 fetuses at a dose of 6 mg/kg/day (87× MRHD based on AUC comparisons). This fetal effect was also noted in the oral rat embryofetal development study conducted with imiquimod. No treatment related effects on <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at 3 mg/kg/day (41× MRHD based on AUC comparisons).</p>
<p>There are no adequate and well-controlled studies in pregnant women. Aldara Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether imiquimod is excreted in human milk following use of Aldara Cream. Because many drugs are excreted in human milk, caution should be exercised when Aldara Cream is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">AK and sBCC are not conditions generally seen within the pediatric population. The safety and efficacy of Aldara Cream for AK or sBCC in patients less than 18 years of age have not been established.</p>
<p>Safety and efficacy in patients with external genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> below the age of 12 years have not been established.</p>
<p>Aldara Cream was evaluated in two randomized, vehicle-controlled, double-blind trials involving 702 pediatric subjects with <span class="product-label-link" type="condition" conceptid="141216" conceptname="Molluscum contagiosum infection">molluscum contagiosum</span> (MC) (470 exposed to Aldara; median age 5 years, range 2–12 years). Subjects applied Aldara Cream or vehicle 3 times weekly for up to 16 weeks. Complete clearance (no MC lesions) was assessed at Week 18. In Study 1, the complete clearance rate was 24% (52/217) in the Aldara Cream group compared with 26% (28/106) in the vehicle group. In Study 2, the clearance rates were 24% (60/253) in the Aldara Cream group compared with 28% (35/126) in the vehicle group. These studies failed to demonstrate efficacy.</p>
<p>Similar to the studies conducted in adults, the most frequently reported adverse reaction from 2 studies in children with <span class="product-label-link" type="condition" conceptid="141216" conceptname="Molluscum contagiosum infection">molluscum contagiosum</span> was <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reaction</span>. Adverse events which occurred more frequently in Aldara-treated subjects compared with vehicle-treated subjects generally resembled those seen in studies in indications approved for adults and also included <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (5% Aldara vs. 3% vehicle) and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (3% Aldara vs. 2% vehicle).</p>
<p><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> was the most frequently reported local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>. Severe local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> reported by Aldara-treated subjects in the pediatric studies included <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (28%), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (8%), <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting (5%), flaking/scaling (5%), erosion (2%) and <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">weeping</span>/exudate (2%).</p>
<p>Systemic absorption of imiquimod across the affected skin of 22 subjects aged 2 to 12 years with extensive MC involving at least 10% of the total body surface area was observed after single and multiple doses at a dosing frequency of 3 applications per week for 4 weeks. The investigator determined the dose applied, either 1, 2 or 3 packets per dose, based on the size of the treatment area and the subject's weight. The overall median peak serum drug concentrations at the end of week 4 was between 0.26 and 1.06 ng/mL except in a 2-year old female who was administered 2 packets of study drug per dose, had a C<span class="Sub">max</span> of 9.66 ng/mL after multiple dosing. Children aged 2–5 years received doses of 12.5 mg (one packet) or 25 mg (two packets) of imiquimod and had median multiple-dose peak serum drug levels of approximately 0.2 or 0.5 ng/mL, respectively. Children aged 6–12 years received doses of 12.5 mg, 25 mg, or 37.5 mg (three packets) and had median multiple dose serum drug levels of approximately 0.1, 0.15, or 0.3 ng/mL, respectively. Among the 20 subjects with evaluable laboratory assessments, the median WBC count decreased by 1.4*10<span class="Sup">9</span>/L and the median absolute neutrophil count decreased by 1.42*10<span class="Sup">9</span>/L.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 215 subjects treated with Aldara Cream in the AK clinical studies, 127 subjects (59%) were 65 years and older, while 60 subjects (28%) were 75 years and older. Of the 185 subjects treated with Aldara Cream in the sBCC clinical studies, 65 subjects (35%) were 65 years and older, while 25 subjects (14%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. No other clinical experience has identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-8"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Underline">Topical</span> overdosing of Aldara Cream could result in an increased incidence of severe local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> and may increase the risk for systemic reactions.</p>
<p>The most clinically serious adverse event reported following multiple oral imiquimod doses of &gt;200 mg (equivalent to imiquimod content of &gt;16 packets) was <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which resolved following oral or intravenous fluid administration.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, purified water, benzyl alcohol, methylparaben, and propylparaben.</p>
<p>Chemically, imiquimod is 1-(2-methylpropyl)-1<span class="Italics">H</span>-imidazo[4,5-c]quinolin-4-amine. Imiquimod has a molecular formula of C<span class="Sub">14</span>H<span class="Sub">16</span>N<span class="Sub">4</span> and a molecular weight of 240.3. Its structural formula is:</p>
<div class="Figure">
<a name="id1383"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c3aed27-7b3f-442e-9f60-f2f5c672c85d&amp;name=aldara-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of Aldara Cream in treating AK and sBCC lesions is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ce252b9f-84d5-41d4-8672-353c4db3ef6d"></a><a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></span></p>
<p>In a study of 18 subjects with AK comparing Aldara Cream to vehicle, increases from baseline in week 2 biomarker levels were reported for CD3, CD4, CD8, CD11c, and CD68 for Aldara Cream treated subjects; however, the clinical relevance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f0e5baa9-b23a-42d8-9f48-8e6f8bc49e24"></a><a name="section-10.2.2"></a><p></p>
<p class="First"><span class="Italics">Superficial Basal Cell Carcinoma</span></p>
<p>An open label study in six subjects with sBCC suggests that treatment with Aldara Cream may increase the infiltration of <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, dendritic cells, and macrophages into the tumor lesion; however, the clinical significance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0c7a2e11-27d5-48e4-8270-6846cb34def2"></a><a name="section-10.2.3"></a><p></p>
<p class="First"><span class="Italics">External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></span></p>
<p>Imiquimod has no direct antiviral activity in cell culture. A study in 22 subjects with genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> comparing Aldara Cream and vehicle shows that Aldara Cream induces mRNA encoding cytokines including interferon-α at the treatment site. In addition HPVL1 mRNA and HPV DNA are significantly decreased following treatment. However, the clinical relevance of these findings is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Systemic absorption of imiquimod across the affected skin of 58 subjects with AK was observed with a dosing frequency of 3 applications per week for 16 weeks. Mean peak serum drug concentrations at the end of week 16 were approximately 0.1, 0.2, and 3.5 ng/mL for the applications to face (12.5 mg imiquimod, 1 single-use packet), scalp (25 mg, 2 packets) and hands/arms (75 mg, 6 packets), respectively.</p>
<a name="_RefID0EONAG"></a><table width="85.94%">
<caption><span>Table 10: Mean Serum Imiquimod Concentration in Adults Following Administration of the Last Topical Dose During Week 16 (<span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span>)</span></caption>
<col width="46%">
<col width="53%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Amount of Aldara Cream applied</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Mean peak serum imiquimod concentration [C<span class="Sub">max</span>]</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12.5 mg (1 packet)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">0.1 ng/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25 mg (2 packets)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.2 ng/mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">75 mg (6 packets)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.5 ng/mL</p></td>
</tr>
</tbody>
</table>
<p>The application surface area was not controlled when more than one packet was used. Dose proportionality was not observed. However it appears that systemic exposure may be more dependent on surface area of application than amount of applied dose. The apparent half-life was approximately 10 times greater with topical dosing than the 2 hour apparent half-life seen following subcutaneous dosing, suggesting prolonged retention of drug in the skin. Mean urinary recoveries of imiquimod and metabolites combined were 0.08 and 0.15% of the applied dose in the group using 75 mg (6 packets) for males and females, respectively following 3 applications per week for 16 weeks.</p>
<p>Systemic absorption of imiquimod was observed across the affected skin of 12 subjects with genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>, with an average dose of 4.6 mg. Mean peak drug concentration of approximately 0.4 ng/mL was seen during the study. Mean urinary recoveries of imiquimod and metabolites combined over the whole course of treatment, expressed as percent of the estimated applied dose, were 0.11 and 2.41% in the males and females, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In an oral (gavage) rat carcinogenicity study, imiquimod was administered to Wistar rats on a 2×/week (up to 6 mg/kg/day) or daily (3 mg/kg/day) dosing schedule for 24 months. No treatment related tumors were noted in the oral rat carcinogenicity study up to the highest doses tested in this study of 6 mg/kg administered 2×/week in female rats (87× MRHD based on weekly AUC comparisons), 4 mg/kg administered 2×/week in male rats (75× MRHD based on weekly AUC comparisons) or 3 mg/kg administered 7×/week to male and female rats (153× MRHD based on weekly AUC comparisons).</p>
<p>In a dermal mouse carcinogenicity study, imiquimod cream (up to 5 mg/kg/application imiquimod or 0.3% imiquimod cream) was applied to the backs of mice 3×/week for 24 months. A statistically significant increase in the incidence of liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas was noted in high dose male mice compared to control male mice (251× MRHD based on weekly AUC comparisons). An increased number of <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">skin papillomas</span> was observed in vehicle cream control group animals at the treated site only. The quantitative composition of the vehicle cream used in the dermal mouse carcinogenicity study is the same as the vehicle cream used for Aldara Cream, minus the active moiety (imiquimod).</p>
<p>In a 52-week dermal photoco-carcinogenicity study, the median time to onset of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumor</span> formation was decreased in hairless mice following chronic topical dosing (3×/week; 40 weeks of treatment followed by 12 weeks of observation) with concurrent exposure to UV radiation (5 days per week) with the Aldara Cream vehicle alone. No additional effect on tumor development beyond the vehicle effect was noted with the addition of the active ingredient, imiquimod, to the vehicle cream.</p>
<p>Imiquimod revealed no evidence of mutagenic or clastogenic potential based on the results of five <span class="Italics">in vitro</span> genotoxicity tests (Ames assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> L5178Y assay, Chinese hamster ovary cell chromosome aberration assay, human lymphocyte chromosome aberration assay and SHE cell transformation assay) and three <span class="Italics">in vivo</span> genotoxicity tests (rat and hamster bone marrow cytogenetics assay and a mouse dominant lethal test).</p>
<p>Daily oral administration of imiquimod to rats, throughout mating, gestation, parturition and lactation, demonstrated no effects on growth, fertility or reproduction, at doses up to 87× MRHD based on AUC comparisons.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-12.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></h2>
<p class="First">In two double-blind, vehicle-controlled clinical studies, 436 subjects with AK were randomized to treatment with either Aldara Cream or vehicle cream 2 times per week for 16 weeks. The studies enrolled subjects with 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions within a 25 cm<span class="Sup">2</span> contiguous treatment area on either the face or scalp. The 25 cm<span class="Sup">2</span> contiguous treatment area could be of any dimensions e.g., 5 cm × 5 cm, 3 cm by 8.3 cm, 2 cm by 12.5 cm. Study subjects ranged from 37 to 88 years of age (median 66 years) and 55% had Fitzpatrick skin type I or II. All Aldara-treated subjects were Caucasians.</p>
<p>On a scheduled dosing day, the study cream was applied to the entire treatment area prior to normal sleeping hours and left on for approximately 8 hours. Twice weekly dosing was continued for a total of 16 weeks. The clinical response of each subject was evaluated 8 weeks after the last scheduled application of study cream. Efficacy was assessed by the complete clearance rate, defined as the proportion of subjects at the 8-week post-treatment visit with no (zero) clinically visible AK lesions in the treatment area. Complete clearance included clearance of all baseline lesions, as well as any new or sub-clinical AK lesions which appeared during therapy.</p>
<p>Complete and partial clearance rates are shown in the table below. The partial clearance rate was defined as the percentage of subjects in whom 75% or more baseline AK lesions were cleared.</p>
<a name="_RefID0EZQAG"></a><table width="100%">
<caption><span>Table 11: Clearance Rates (AK)</span></caption>
<col width="12%">
<col width="68%">
<col width="20%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Complete Clearance Rates (100% AK Lesions Cleared)</span></p></td></tr>
<tr>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Aldara Cream</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Vehicle</span></p></td>
</tr>
<tr>
<td align="center"><p class="First">Study AK1</p></td>
<td align="center"><p class="First">46% (49/107)</p></td>
<td align="center"><p class="First">3% (3/110)</p></td>
</tr>
<tr>
<td align="center"><p class="First">Study AK2</p></td>
<td align="center"><p class="First">44% (48/108)</p></td>
<td align="center"><p class="First">4% (4/111)</p></td>
</tr>
<tr><td align="center" colspan="3"><p class="First"><span class="Bold">Partial and Complete Clearance Rates (75% or More Baseline AK Lesions Cleared)</span></p></td></tr>
<tr>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Aldara Cream</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Vehicle</span></p></td>
</tr>
<tr>
<td align="center"><p class="First">Study AK1</p></td>
<td align="center"><p class="First">60% (64/107)</p></td>
<td align="center"><p class="First">10% (11/110)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First">Study AK2</p></td>
<td class="Botrule" align="center"><p class="First">58% (63/108)</p></td>
<td class="Botrule" align="center"><p class="First">14% (15/111)</p></td>
</tr>
</tbody>
</table>
<p>Sub-clinical AK lesions may become apparent in the treatment area during treatment with Aldara Cream. During the course of treatment, 48% (103/215) of subjects experienced an increase in AK lesions relative to the number present at baseline within the treatment area. Subjects with an increase in AK lesions had a similar response to those with no increase in AK lesions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-12.2"></a><p></p>
<h2>14.2 Superficial Basal Cell Carcinoma</h2>
<p class="First">In two double-blind, vehicle-controlled clinical studies, 364 subjects with primary sBCC were treated with Aldara Cream or vehicle cream 5 times per week for 6 weeks. Target tumors were biopsy-confirmed sBCC and had a minimum area of 0.5 cm<span class="Sup">2</span> and a maximum diameter of 2.0 cm (4.0 cm<span class="Sup">2</span>). Target tumors were not to be located within 1.0 cm of the hairline, or on the anogenital area or on the hands or feet, or to have any atypical features. The population ranged from 31–89 years of age (median 60 years) and 65% had Fitzpatrick skin type I or II. On a scheduled dosing day, study cream was applied to the target tumor and approximately 1 cm (about 1/3 inch) beyond the target tumor prior to normal sleeping hours, and 5 times per week dosing was continued for a total of 6 weeks. The target tumor area was clinically assessed 12 weeks after the last scheduled application of study cream. The entire target tumor was then excised and examined histologically for the presence of tumor.</p>
<p>Efficacy was assessed by the complete response rate defined as the proportion of subjects with clinical (visual) and histological clearance of the sBCC lesion at 12 weeks post-treatment. Of Aldara treated subjects, 6% (11/178) who had both clinical and histological assessments post-treatment, and who appeared to be clinically clear had evidence of tumor on excision of the clinically-clear treatment area.</p>
<p>Data on composite clearance (defined as both clinical and histological clearance) are shown in the following table.</p>
<a name="_RefID0E5TAG"></a><table width="80%">
<caption><span>Table 12: Composite Clearance Rates at 12 Weeks Post-Treatment for Superficial Basal Cell Carcinoma</span></caption>
<col width="30%">
<col width="32%">
<col width="30%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Study</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Aldara Cream</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Vehicle Cream</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Study sBCC1</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">70% (66/94)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">2% (2/89)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Study sBCC2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">80% (73/91)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1% (1/90)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">Total</p></td>
<td class="Botrule Rrule" align="center"><p class="First">75% (139/185)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% (3/179)</p></td>
</tr>
</tbody>
</table>
<p>A separate 5-year, open-label study was conducted to assess the recurrence of sBCC treated with Aldara Cream applied once daily 5 days per week for 6 weeks. Target tumor inclusion criteria were the same as for the studies described above. At 12-weeks post-treatment, subjects were clinically evaluated for evidence of persistent sBCC (no histological assessment). Subjects with no clinical evidence of sBCC entered the long-term follow-up period. At the 12 week post-treatment assessment, 90% (163/182) of the subjects enrolled had no clinical evidence of sBCC at their target site and 162 subjects entered the long-term follow-up period for up to 5 years. Two year (24 month) follow-up data are available from this study and are presented in the table below:</p>
<a name="_RefID0EMWAG"></a><table width="100%">
<caption><span>Table 13: Estimated Clinical Clearance Rates for Superficial Basal Cell Carcinoma Follow-up Period</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Follow-up</span><br><span class="Bold">visit after 12-week post-treatment assessment</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">No. of</span><br><span class="Bold">Subjects who remained</span><br><span class="Bold">clinically clear</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">No. of</span><br><span class="Bold">Subjects</span><br><span class="Bold">with sBCC</span><br><span class="Bold">recurrence</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">No. of Subjects</span><br><span class="Bold">who discontinued</span><br><span class="Bold">at this visit with</span><br><span class="Bold">no sBCC</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold">Estimated Rate</span><br><span class="Bold">of Subjects who Clinically Cleared and remained Clear</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Reasons for discontinuation included <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, non-compliance, entry criteria violations, personal reasons, and treatment of nearby sBCC tumor.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Estimated rate of subjects who clinically cleared and remained clear are estimated based on the time to event analysis employing the life table method beginning with the rate of clinical clearance at 12 weeks post-treatment.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><p class="First">Month 3</p></td>
<td class="Rrule Toprule" align="center"><p class="First">153</p></td>
<td class="Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Rrule Toprule" align="center"><p class="First">87%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">Month 6</p></td>
<td class="Rrule" align="center"><p class="First">149</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
<td class="Rrule" align="center"><p class="First">85%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">Month 12</p></td>
<td class="Rrule" align="center"><p class="First">143</p></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">84%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">Month 24</p></td>
<td class="Botrule Rrule" align="center"><p class="First">139</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">79%</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-12.3"></a><p></p>
<h2>14.3 External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></h2>
<p class="First">In a double-blind, placebo-controlled clinical study, 209 otherwise healthy subjects 18 years of age and older with genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> were treated with Aldara Cream or vehicle control 3 times per week for a maximum of 16 weeks. The median baseline <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> area was 69 mm<span class="Sup">2</span> (range 8 to 5525 mm<span class="Sup">2</span>). Subject accountability is shown in the figure below.</p>
<table width="100%">
<col width="100%">
<tbody class="Headless">
<tr class="First"><td class="Toprule"><p class="First"><span class="Bold">Figure 1: Subject Accountability (External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span>)</span></p></td></tr>
<tr class="Last"><td class="Botrule" align="center">
<a name="id1657"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c3aed27-7b3f-442e-9f60-f2f5c672c85d&amp;name=aldara-02.jpg">
</td></tr>
</tbody>
</table>
<p>*The other subjects were either lost to follow-up or experienced recurrences.</p>
<p>Data on complete clearance are listed in Table 14. The median time to complete <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> clearance was 10 weeks.</p>
<a name="_RefID0EK1AG"></a><table width="100%">
<caption><span>Table 14: Complete Clearance Rates (External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span>) - Study EGW1</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Treatment</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Subjects with Complete Clearance of <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">Warts</span></span></th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Subjects Without</span><br><span class="Bold">Follow-up</span>
</th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Subjects with <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">Warts</span> Remaining at Week 16</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Overall</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First">Aldara Cream (n=109)</p></td>
<td align="center"><p class="First">54 (50%)</p></td>
<td align="center"><p class="First">19 (17%)</p></td>
<td align="center"><p class="First">36 (33%)</p></td>
</tr>
<tr>
<td><p class="First">Vehicle (n=100)</p></td>
<td align="center"><p class="First">11 (11%)</p></td>
<td align="center"><p class="First">27 (27%)</p></td>
<td align="center"><p class="First">62 (62%)</p></td>
</tr>
<tr>
<td><p class="First">Females</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Aldara Cream (n=46)</p></td>
<td align="center"><p class="First">33 (72%)</p></td>
<td align="center"><p class="First">5 (11%)</p></td>
<td align="center"><p class="First">8 (17%)</p></td>
</tr>
<tr>
<td><p class="First">Vehicle (n=40)</p></td>
<td align="center"><p class="First">8 (20%)</p></td>
<td align="center"><p class="First">13 (33%)</p></td>
<td align="center"><p class="First">19 (48%)</p></td>
</tr>
<tr>
<td><p class="First">Males</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Aldara Cream (n=63)</p></td>
<td align="center"><p class="First">21 (33%)</p></td>
<td align="center"><p class="First">14 (22%)</p></td>
<td align="center"><p class="First">28 (44%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Vehicle (n=60)</p></td>
<td class="Botrule" align="center"><p class="First">3 (5%)</p></td>
<td class="Botrule" align="center"><p class="First">14 (23%)</p></td>
<td class="Botrule" align="center"><p class="First">43 (72%)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Aldara (imiquimod) Cream, 5%, is supplied in single-use packets which contain 250 mg of the cream. Available as: box of 12 packets NDC 99207-260-12. Store at 4°–25°C (39°–77°F).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_f9e4f8d7-73aa-4d95-a9fa-85568ca67dbb"></a><a name="section-13.1"></a><p></p>
<p class="First">Avoid freezing.</p>
<p><span class="Bold"><span class="Italics">Keep out of reach of children.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See <a href="#S17.1">FDA-Approved Patient Labeling</a></span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_6ddec095-d767-49d9-b087-e44a51f46bbe"></a><a name="section-15"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 General Information: All Indications</h2>
<p class="First">Aldara Cream should be used as directed by a physician <span class="Italics">[see <a href="#S2">Dosage and Administration (2)</a>].</span> Aldara Cream is for external use only. Contact with the eyes, lips and nostrils should be avoided <span class="Italics">[see <a href="#S1">Indications and Usage (1)</a></span>and <span class="Italics"><a href="#S2">Dosage and Administration (2)</a>].</span> The treatment area should not be bandaged or otherwise occluded. Partially-used packets should be discarded and not reused. The prescriber should demonstrate the proper application technique to maximize the benefit of Aldara Cream therapy.</p>
<p>It is recommended that patients wash their hands before and after applying Aldara cream.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>: All Indications</h2>
<p class="First">Patients may experience local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> during treatment with Aldara Cream (even with normal dosing). Potential local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, erosions/ulcerations, <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">weeping</span>/exudate, flaking/scaling/dryness, and <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting. These reactions can range from mild to severe in intensity and may extend beyond the application site onto the surrounding skin. Patients may also experience <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and/or burning <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>].</span></p>
<p>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may be of such intensity that patients may require rest periods from treatment. Treatment with Aldara Cream can be resumed after the <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> has subsided, as determined by the physician. Patients should contact their physician promptly if they experience any sign or symptom at the application site that restricts or prohibits their daily activity or makes continued application of the cream difficult.</p>
<p>Because of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, during treatment and until healed, the treatment area is likely to appear noticeably different from normal skin. Localized hypopigmentation and hyperpigmentation have been reported following use of Aldara Cream. These skin color changes may be permanent in some patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Systemic Reactions: All Indications</h2>
<p class="First">Patients may experience flu-like systemic signs and symptoms during treatment with Aldara Cream (even with normal dosing). Systemic signs and symptoms may include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>].</span> An interruption of dosing should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Patients Being Treated for <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span> (AK)</h2>
<p class="First">Dosing is 2 times per week for a full 16 weeks, unless otherwise directed by the physician. However, the treatment period should not be extended beyond 16 weeks due to missed doses or rest periods <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>].</span></p>
<p>It is recommended that the treatment area be washed with mild soap and water 8 hours following Aldara Cream application.</p>
<p>Most patients using Aldara Cream for the treatment of AK experience <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, flaking/scaling/dryness and <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting at the application site with normal dosing <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>].</span></p>
<p>Use of sunscreen is encouraged, and patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using Aldara Cream <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></p>
<p>Sub-clinical AK lesions may become apparent in the treatment area during treatment and may subsequently resolve <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Patients Being Treated for Superficial Basal Cell Carcinoma (sBCC)</h2>
<p class="First">Dosing is 5 times per week for a full 6 weeks, unless otherwise directed by the physician. However, the treatment period should not be extended beyond 6 weeks due to missed doses or rest periods <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span></p>
<p>It is recommended that the treatment area be washed with mild soap and water 8 hours following Aldara Cream application <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span></p>
<p>Most patients using Aldara Cream for the treatment of sBCC experience <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, erosion, <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusting and flaking/scaling at the application site with normal dosing <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>].</span></p>
<p>Use of sunscreen is encouraged, and patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using Aldara Cream <span class="Italics">[see<a href="#S5.3"> Warnings and Precautions (5.7)</a>].</span></p>
<p>The clinical outcome of therapy can be determined after resolution of <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> and/or local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</p>
<p>Patients with sBCC treated with Aldara Cream should have regular follow-up to re-evaluate the treatment site <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6 Patients Being Treated for External <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></h2>
<p class="First">Dosing is 3 times per week to external genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>. Aldara Cream treatment should continue until there is total clearance of the genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> or for a maximum of 16 weeks.</p>
<p>It is recommended that the treatment area be washed with mild soap and water 6–10 hours following Aldara Cream application.</p>
<p>It is common for patients to experience local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, erosion, <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriation</span>/flaking, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> at the site of application or surrounding areas. Most <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> are mild to moderate.</p>
<p>Sexual (genital, anal, oral) contact should be avoided while Aldara Cream is on the skin. Application of Aldara Cream in the vagina is considered internal and should be avoided. Female patients should take special care if applying the cream at the opening of the vagina because local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> on the delicate moist surfaces can result in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or severe <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and may cause difficulty in passing urine, or inability to urinate.</p>
<p>Uncircumcised males treating <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> under the foreskin should retract the foreskin and clean the area daily.</p>
<p>New <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> may develop during therapy, as Aldara Cream is not a cure.</p>
<p>The effect of Aldara Cream on the transmission of genital/perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> is unknown.</p>
<p>Aldara Cream may weaken condoms and vaginal diaphragms; therefore, concurrent use is not recommended.</p>
<p>Should severe local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occur, the cream should be removed by washing the treatment area with mild soap and water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_013babe1-86fe-40ac-8e54-4d9e370f825a"></a><a name="section-15.7"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">Manufactured for:</span></p>
<p>Valeant Pharmaceuticals North America LLC</p>
<p>Bridgewater, NJ 08807 USA</p>
<p><span class="Bold">by:</span><br>3M Health Care Limited<br>Loughborough LE11 1EP United Kingdom</p>
<p>Made in UK</p>
<p>Rev 08/14<br>9415900</p>
<p>620423471</p>
<p>Aldara is a registered trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.</p>
<div class="Section" data-sectionCode="68498-5">
<a name="ID_4878d63c-284a-42cd-9a51-1bcd9bd69fb0"></a><a name="section-15.7.1"></a><p></p>
<h3><span class="Bold">Patient Information</span></h3>
<p class="First"><span class="Bold">ALDARA<span class="Sup">®</span></span></p>
<p>[al dar’ a]</p>
<p><span class="Bold">Cream, 5%</span></p>
<p><span class="Bold">(imiquimod)</span></p>
<p><span class="Bold">IMPORTANT: Not for mouth, eye, or vaginal use</span></p>
<p>Read the Patient Information that comes with Aldara Cream before you start using it and each time you get a refill.  There may be new information.  This leaflet does not take the place of talking with your healthcare provider about your medical condition or treatment.  If you do not understand the information, or have any questions about Aldara Cream, talk with your healthcare provider or pharmacist.</p>
<p><span class="Bold">What is Aldara Cream?</span></p>
<p>Aldara Cream is a skin use only (topical) medicine used to treat:</p>
<dl>
<dt>•</dt>
<dd>external genital and perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> in people 12 years and older.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> in adults with normal immune systems.  <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic keratosis</span> is caused by too much sun exposure.  </dd>
<dt>•</dt>
<dd>superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.  </dd>
</dl>
<p>This skin cancer needs to be diagnosed by your healthcare provider.</p>
<p>Aldara Cream is used in different ways for the three different skin conditions it is used to treat.  It is very important that you follow the instructions for your skin condition. Talk to your healthcare provider if you have questions.</p>
<p>Aldara Cream does not work for everyone. Aldara Cream will not cure your genital or perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>.  New <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> may develop during treatment with Aldara Cream.  It is not known if Aldara Cream can stop you from spreading genital or perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> to other people.  For your own health and the health of others, it is important to practice safer sex. Talk to your healthcare provider about safer sex practices.</p>
<p><span class="Bold">Who should not use Aldara Cream?</span></p>
<dl>
<dt>•</dt>
<dd>Aldara Cream has not been studied in children under 12 years old for external genital and perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>.</dd>
<dt>•</dt>
<dd>Aldara Cream has not been studied in children under 18 years old for <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> or superficial basal cell carcinoma. Children usually do not get <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> or basal cell carcinoma.</dd>
</dl>
<p><span class="Bold">Before using Aldara Cream, tell your healthcare provider:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">about all your medical conditions, including if you</span><dl>
<dt>•</dt>
<dd>
<span class="Bold">are pregnant or planning to become pregnant. </span>It is not known if Aldara Cream can harm your unborn baby.</dd>
<dt>•</dt>
<dd>
<span class="Bold">are breastfeeding. </span>It is not known if Aldara Cream passes into your milk and if it can harm your baby.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">about all the medicines you take including prescription and non-prescription medicines, vitamins and herbal supplements</span>.  Especially tell your healthcare provider if you have had other treatments for genital or perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>, or <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span>, or superficial basal cell carcinoma.  Aldara Cream should not be used until your skin has healed from other treatments.</dd>
</dl>
<p><span class="Bold">How should I use Aldara Cream?</span></p>
<dl>
<dt>•</dt>
<dd>Use Aldara Cream exactly as prescribed by your healthcare provider.  <span class="Bold">Aldara Cream is for skin use only.  Do not take by mouth or use in or near your eyes, lips or nostrils.  </span>Do not use Aldara Cream unless your healthcare provider has taught you the right way to use it.  Talk to your healthcare provider if you have any questions.</dd>
<dt>•</dt>
<dd>Aldara Cream is used for several skin conditions.  <span class="Bold">Use Aldara Cream only on the area of your body to be treated.  </span>Your healthcare provider will tell you where to apply Aldara Cream and how often and for how long to apply it for your condition.  Do not use Aldara Cream longer than prescribed. Using too much Aldara Cream, or using it too often, or for too long can increase your chances for having a severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> or other side effect.  Talk to your healthcare provider if Aldara Cream does not work for you.</dd>
</dl>
<p><span class="Bold">For external genital and perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span></span> Aldara Cream is usually used once a day for 3 days a week:</p>
<dl>
<dt>•</dt>
<dd>Monday, Wednesday and Friday, or </dd>
<dt>•</dt>
<dd>Tuesday, Thursday and Saturday</dd>
</dl>
<p>For these conditions, Aldara Cream is usually left on the skin for 6 to 10 hours.  Treatment should continue until the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> are completely gone, or up to 16 weeks.</p>
<p><span class="Bold">For <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span></span> Aldara Cream is usually used once a day for 2 days a week, 3 to 4 days apart, such as:</p>
<dl>
<dt>•</dt>
<dd>Monday and Thursday, or</dd>
<dt>•</dt>
<dd>Tuesday and Friday</dd>
</dl>
<p>For this condition, Aldara Cream is usually left on the skin for about 8 hours.  Treatment should continue for the full 16 weeks even if all <span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">actinic keratosis</span> appear to be gone, unless you are told otherwise by your healthcare provider.  The area you treat with Aldara Cream should be no larger than approximately the size of your forehead or one cheek (for example 2 inches by 2 inches), unless otherwise directed by your healthcare provider.</p>
<p><span class="Bold">For superficial basal cell carcinoma</span> Aldara Cream is usually used once a day for 5 days a week:</p>
<dl>
<dt>•</dt>
<dd>Monday, Tuesday, Wednesday, Thursday and Friday</dd>
</dl>
<p>For this condition, Aldara Cream is usually left on the skin for about 8 hours.  Your healthcare provider will show you how much Aldara Cream to apply to your superficial basal cell carcinoma.  You should also apply Aldara Cream to a small area of skin all <span class="Underline">around</span> the superficial basal cell carcinoma.  This small area of skin should be about the size of your fingertip.  Treatment should continue for the full 6 weeks, even if the superficial basal cell carcinoma appears to be gone, unless you are told otherwise by your healthcare provider.</p>
<p><span class="Bold">Applying Aldara Cream</span></p>
<p>Aldara Cream should be applied just before your bedtime.</p>
<dl>
<dt>•</dt>
<dd>Wash the area to be treated with mild soap and water.  Allow the area to dry.<dl>
<dt>•</dt>
<dd>Uncircumcised males treating <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> under their penis foreskin must pull their foreskin back and clean before treatment, and clean daily during the weeks of treatment.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Wash your hands.</dd>
<dt>•</dt>
<dd>Open a new packet of Aldara Cream just before use.</dd>
<dt>•</dt>
<dd>Apply a thin layer of Aldara Cream <span class="Bold">only </span>to the affected area or areas to be treated.  Do not use more Aldara Cream than is needed to cover the treatment area.</dd>
<dt>•</dt>
<dd>Rub the cream in all the way to the affected area or areas.<dl>
<dt>•</dt>
<dd>Do not get Aldara Cream in your eyes.</dd>
<dt>•</dt>
<dd>Do not get Aldara Cream in the anus when applying to perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span>.</dd>
<dt>•</dt>
<dd>Female patients treating <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span> must be careful when applying Aldara Cream around the vaginal opening.  Female patients should take special care if applying the cream at the opening of the vagina because local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> on the delicate moist surfaces can cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and may cause problems passing urine.  Do not put Aldara Cream in your vagina or on the skin around the genital <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span>.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Do not cover the treated area with an airtight bandage.  Cotton gauze dressings can be used.  Cotton underwear can be worn after applying Aldara Cream to the genital or perianal area.</dd>
<dt>•</dt>
<dd>Safely throw away the open packet of Aldara Cream so that children and pets cannot get it.  The open packet should be thrown away even if all the Aldara Cream was not completely used.</dd>
<dt>•</dt>
<dd>After applying Aldara Cream, <span class="Bold">wash your hands well.</span>
</dd>
<dt>•</dt>
<dd>Leave the cream on the affected area or areas for the time prescribed by your healthcare provider.  The length of time that Aldara Cream is left on the skin is not the same for the different skin conditions that Aldara Cream is used to treat.  Do not bathe or get the treated area wet before the right time has passed.  Do not leave Aldara Cream on your skin longer than prescribed.</dd>
<dt>•</dt>
<dd>After the right amount of time has passed, wash the treated area or areas with mild soap and water.</dd>
<dt>•</dt>
<dd>If you forget to apply Aldara Cream, apply the missed dose of cream as soon as you remember and then continue on your regular schedule.</dd>
<dt>•</dt>
<dd>If you get Aldara Cream in your mouth or in your eyes rinse well with water right away.</dd>
</dl>
<p><span class="Bold">What should I avoid while using Aldara Cream?</span></p>
<dl>
<dt>•</dt>
<dd>Do not cover the treated site with bandages or other closed dressings.  Cotton gauze dressings are okay to use, if needed.  Cotton underwear can be worn after treating the genital or perianal area.</dd>
<dt>•</dt>
<dd>Do not apply Aldara Cream in or near the eyes, lips or nostrils, or in the vagina or anus.</dd>
<dt>•</dt>
<dd>Do not use sunlamps or tanning beds, and avoid sunlight as much as possible during treatment with Aldara Cream. Use sunscreen and wear protective clothing if you go outside during daylight.</dd>
<dt>•</dt>
<dd>Do not have sexual contact including genital, anal, or oral sex when Aldara Cream is on your genital or perianal skin.  Aldara Cream may weaken condoms and vaginal diaphragms.  This means they may not work as well to prevent pregnancy.  For your own health and the health of others, it is important to practice safer sex.  Talk to your healthcare provider about safer sex practices.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of Aldara Cream?</span></p>
<p><span class="Bold">The most common side effects with Aldara Cream </span>are <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> at the treatment site including:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>•</dt>
<dd>a sore, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span></dd>
<dt>•</dt>
<dd>skin that becomes hard or thickened</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin peeling</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span> and crusting</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>•</dt>
<dd>burning</dd>
<dt>•</dt>
<dd>changes in skin color that do not always go away</dd>
</dl>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="138825" conceptname="Actinic keratosis">Actinic Keratosis</span></span></p>
<p><span class="Bold">During treatment and until the skin has healed, your skin in the treatment area is likely to appear noticeably different from normal skin.  </span>Side effects, such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and burning are common at the site where Aldara Cream is applied, and sometimes the side effects go outside of the area where Aldara Cream was applied.  <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span>, small open sores and drainage may also be experienced with use of Aldara Cream.  You may also experience <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and/or burning. Actinic keratoses that were not seen before may appear during treatment and may later go away.  If you have questions regarding treatment or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, please talk with your healthcare provider.</p>
<p><span class="Bold">Superficial Basal Cell Carcinoma</span></p>
<p><span class="Bold">During treatment and until the skin has healed, your skin in the treatment area is likely to appear noticeably different from normal skin. </span>Side effects, such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and a sore are common at the site where Aldara Cream is applied.  You may also experience <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or burning.  Your healthcare provider will need to check the area that was treated after your treatment is finished to make sure that the skin cancer is gone.  Superficial basal cell carcinoma can come back. The chances of it coming back are higher as time passes.  <span class="Bold">It is very important to have regular follow-up visits with your healthcare provider to check the area to make sure your skin cancer has not come back.  Ask your healthcare provider how often you should have your skin checked.  </span>Talk with your healthcare provider if you have questions about your treatment or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</p>
<p><span class="Bold">External Genital and Perianal <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">Warts</span></span></p>
<p>Patients should be aware that new <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> may develop during treatment, as Aldara Cream is not a cure.  Many people see reddening or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> on or around the application site during the course of treatment.  If you have questions regarding treatment or local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, please talk with your healthcare provider.</p>
<p>You have a higher chance for severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> if you use too much Aldara Cream or use it the wrong way.  <span class="Bold">Stop Aldara Cream right away and call your healthcare provider if you get any <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that affect your daily activities, or that do not go away.  </span>Sometimes, Aldara Cream must be stopped for a while to allow your skin to heal.  Talk to your healthcare provider if you have questions about your treatment or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</p>
<p>Other side effects of Aldara Cream include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen lymph nodes</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.</p>
<p>If the reactions seem excessive, if either skin breaks down or sores develop during the first week of treatment, if flu-like symptoms develop or if you begin to not feel well at anytime, contact your healthcare provider.</p>
<p>These are not all the side effects of Aldara Cream.  For more information, ask your healthcare provider or pharmacist. </p>
<p><span class="Bold">How do I store Aldara Cream?</span></p>
<dl>
<dt>•</dt>
<dd>Store Aldara Cream at 39° to 77°F (4° to 25°C).  Do not freeze.</dd>
<dt>•</dt>
<dd>Safely throw away Aldara Cream that is out of date or that you do not need.</dd>
<dt>•</dt>
<dd><span class="Bold">Keep Aldara Cream and all medicines out of the reach of children.</span></dd>
</dl>
<p><span class="Bold">General information about Aldara Cream</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.  Do not use Aldara Cream for a condition for which it was not prescribed.  Do not give Aldara Cream to other people, even if they have the same symptoms you have.</p>
<p>This leaflet summarizes the most important information about Aldara Cream.  If you would like more information, talk with your healthcare provider.  You can ask your pharmacist or healthcare provider for information about Aldara Cream that is written for the healthcare provider.  If you have other questions about Aldara Cream, call 1-800-321-4576.</p>
<p><span class="Bold">What are the ingredients in Aldara Cream?</span></p>
<p><span class="Bold">Active Ingredient: </span>imiquimod</p>
<p><span class="Bold">Inactive ingredients: </span>isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, purified water, benzyl alcohol, methylparaben, and propylparaben.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">VALEANT</span></p>
<p><span class="Bold">Manufactured for:</span></p>
<p>Valeant Pharmaceuticals North America LLC</p>
<p>Bridgewater, NJ 08807 USA</p>
<p><span class="Bold">by:</span></p>
<p>3M Health Care Limited </p>
<p>Loughborough LE11 1EP United Kingdom</p>
<p>Made in UK</p>
<p>Rev. 08/14</p>
<p>9416000</p>
<p>620423489</p>
<p>ALDARA is a registered trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_66657938-f08f-42f4-85ca-9e4b1b270c85"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.25g Packet Carton</span></p>
<p>NDC 99207-260-12</p>
<p><span class="Bold"><span class="Italics">Cream, 5%</span></span></p>
<p><span class="Bold">Aldara</span><span class="Sup">®</span><br>(IMIQUIMOD)</p>
<p>For Topical Use Only<br>Not for Ophthalmic, Oral<br>or Intravaginal Use</p>
<p><span class="Bold">Rx only </span></p>
<p><span class="Bold">12</span><br><span class="Bold">single use</span><br><span class="Bold">packets</span></p>
<p>Net Wt. Per Packet<br><span class="Bold">0.25 g</span></p>
<p>Net Wt. Per Box<br><span class="Bold">3 g</span></p>
<div class="Figure">
<a name="id1932"></a><img alt="Aldara Imiquimod Carton " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c3aed27-7b3f-442e-9f60-f2f5c672c85d&amp;name=aldara-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALDARA 		
					</strong><br><span class="contentTableReg">imiquimod cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:99207-260</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>imiquimod</strong> (imiquimod) </td>
<td class="formItem">imiquimod</td>
<td class="formItem">50 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOSTEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 60</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITAN MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:99207-260-01</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.25 g in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:99207-260-12</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">0.25 g in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020723</td>
<td class="formItem">11/28/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Medicis Pharmaceutical Corp
							(182837492)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">3M Health Care Limited</td>
<td class="formItem"></td>
<td class="formItem">218829455</td>
<td class="formItem">MANUFACTURE(99207-260)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>27a5df6e-8370-4b2b-a86b-d753c034cbbd</div>
<div>Set id: 0c3aed27-7b3f-442e-9f60-f2f5c672c85d</div>
<div>Version: 4</div>
<div>Effective Time: 20140801</div>
</div>
</div> <div class="DistributorName">Medicis Pharmaceutical Corp</div></p>
</body></html>
